Eagle's Eye View: Your Weekly CV Update From ACC.org

This week, the discussion centers around groundbreaking clinical trials from the recent TCT conference. The EARLY TAVR trial compares TAVR options versus clinical surveillance for aortic stenosis. Insights into the TRISCEND II trial reveal innovations for treating severe tricuspid regurgitation. The ECLIPSE study examines the benefits of orbital atherectomy before PCI. Finally, the CLEAR SYNERGY trial investigates colchicine effects post-PCI for STEMI patients. These trials are set to reshape cardiovascular treatment approaches.

In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart failure and reduced ejection fraction (HFrEF). He then explores the effect of race and sacubitril/valsartan use in HF patients documented in a pooled analysis of the PARADIGM-HF and PARAGON-HF trials. Finally, Dr. Eagle discusses the utility of systolic blood pressure (BP) polygenic risk scores and the treatment response in people with hypertension.    Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at anthracycline cardiotoxicity in treatment of cancer patients. He then explores a scientific statement from the American Heart Association on cardiac arrhythmias and autonomic dysfunction associated with COVID-19. Finally, Dr. Eagle discusses the SWEDEHEART registry and intensive early and sustained lowering of non–HDL cholesterol after MI and prognosis.    Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at an individual patient data meta-analysis of semaglutide and blood pressure (BP). He then explores an analysis from COMBINE-AF on heart failure (HF) risk assessment using biomarkers in patients with atrial fibrillation. Finally, Dr. Eagle discusses short-term dual antiplatelet therapy (DAPT) after drug-eluting stenting in patients with acute coronary syndrome (ACS).  Subscribe to Eagle’s Eye View  

Discover the impact of COVID vaccination on cardiovascular events, highlighted by a study of over 8 million patients showing reduced risks. Delve into the long-term effects of septal reduction therapy in obstructive hypertrophic cardiomyopathy. Finally, compare varying clinical practice guidelines for managing acute pulmonary embolism. Tune in for a blend of cutting-edge research and practical insights!

In this week’s View, Dr. Eagle looks at sex-specific differences in alive hospital discharge following abdominal aortic aneurysm (AAA) repair. He then explores how diffuse interstitial fibrosis of the myocardium predicts outcomes in moderate and asymptomatic severe aortic stenosis. Finally, Dr. Eagle discusses the value of mineralocorticoid receptor antagonists (MRAs) in heart failure (HF).    Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at risk stratification in nonischemic dilated cardiomyopathy using CMR imaging. He then discusses the recent update of the Guideline for Perioperative CV Management for Noncardiac Surgery. Finally, Dr. Eagle talks about a review article on lipoprotein(a) and CVD.   Subscribe to Eagle’s Eye View  

This discussion dives into long-term outcomes for patients with recurrent pericarditis and how machine learning is reshaping predictions. It also highlights the promising role of polygenic risk scores in assessing cardiovascular disease risk. Furthermore, the management of aortic disease in children with FBN1-related Marfan syndrome is examined, emphasizing personalized imaging strategies and treatment plans to improve health outcomes. Complex yet crucial topics come together to shed light on advancing cardiovascular care.

In this special edition of Eagle’s Eye View, Dr. Eagle summarizes the most important trials that were featured at the ESC Congress 2024, August 30 to September 2—eight trials that could have significant influence on your day-to-day practice. They include: FINEARTS-HF, exploring the benefits of finerenone in patients with HFmrEF or HFpEF; SCOFF, asking if fasting prior to cath lab procedures is necessary; SENIOR-RITA on CV management in frail adults; SHAM-PVI, exploring pulmonary vein isolation vs. sham intervention in patients with asymptomatic AFib; ASSURE DES, examining continuing vs. interruptive aspirin therapy before noncardiac surgery in patients with DES; Stop-or-Not, on the continuation vs. discontinuation of RASIs prior to major noncardiac surgery; ABYSS, exploring the impact of interrupting or continuing beta-blocker treatment in patients with a history of MI; and  RESHAPE-HF2, on the impact of M-TEER on patients with FMR and symptomatic HF.   Subscribe to Eagle’s Eye View  

Discover the latest advancements in cardiovascular care! The discussion includes the use of temporary mechanical support for cardiogenic shock following a heart attack. Learn about the benefits of anticoagulation in patients with device-detected atrial fibrillation. The effectiveness of semaglutide in treating heart failure with mildly reduced or preserved ejection fraction is also highlighted. These insights aim to improve treatment strategies and patient outcomes.